Global markets have entered a period of recalibration as the war between the U.S. and Iran ripples through one of the world’s most critical energy arteries. The disruption of oil and gas shipments through the Strait of Hormuz has tightened supply expectations and stirred fresh volatility across energy markets. Investors, as they often do in uncertain times, have turned to history for guidance. In the aftermath of major oil supply shocks, select sectors tend to rise above the noise. Energy, consumer stapl ...

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $961 million, a reported sales increase of 6.2% and constant currency growth of 2.5% compared to the prior year [9][10] - Adjusted EBITDA margins declined 10 basis points to 14.1%, with a $15 million impact from tariffs [10] - Adjusted EPS for the quarter was $0.27, up 4.9% from the prior year [10] - Full-year sales were $3.68 billion, representing a reported sales decline of 3% and a 4.3% decline on a constant currency basis [14][15] - Full-year adjusted EPS was $1.60, down 4.6% year-on-year [15] Business Line Data and Key Metrics Changes - The CTS segment saw constant currency sales decline 1.9%, with lower sales in CAD/CAM in Europe and the rest of the world, partially offset by high single-digit growth in the U.S. [11] - The EDS segment, which includes endo, resto, and preventative products, experienced a 4% increase in constant currency sales, led by a 17% growth in preventative products [12] - OIS segment sales increased 6.9% in constant currency, while IPS declined due to lower implant volumes [12] - Wellspect HealthCare constant currency sales increased 1.9%, with 15% growth in the U.S. [12] Market Data and Key Metrics Changes - In China, implant sales saw a single-digit growth in the first half of the year but a double-digit decline in the second half due to changes in buying behavior [13] - Premium implants declined, while value implants were slightly down, primarily due to challenges in China [13] Company Strategy and Development Direction - The company is focused on a 24-month Return-to-Growth action plan aimed at restoring momentum and delivering sustained profitable growth [17] - The plan includes five pillars: customer-centric mindset, reigniting sustainable growth, empowering performance, scaling the organization, and financial strength [17][18] - The company aims to strengthen its U.S. business and improve its competitive position through strategic partnerships and enhanced sales force training [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's potential and the effectiveness of the Return-to-Growth plan [7][29] - The company anticipates a net sales range of $3.5 billion to $3.6 billion for 2026, reflecting a -3% to -1% operational growth [28] - Management emphasized that the return to health is not market-dependent and that improvements will come from better execution [75] Other Important Information - The company initiated a restructuring program expected to unlock approximately $120 million annually, which will be reinvested in the Return-to-Growth action plan [26] - The decision to eliminate dividends will allow for capital reallocation towards debt retirement and share repurchases [27] Q&A Session Summary Question: Discussion on dividend elimination and capital deployment - Management indicated that the elimination of dividends would free up $128 million annually for capital deployment, focusing on debt retirement first and then share repurchases [32][33] Question: Impact of new dealer inventory model on revenue - Management explained that transitioning to a drop ship model would result in an estimated revenue headwind of about $30 million, expected to be resolved in the first half of 2026 [35][36] Question: Timing of recent dealer agreements and their impact - Management noted that benefits from new dealer agreements are not significantly included in guidance and are expected to materialize in the latter half of 2026 [39][40] Question: R&D spending and product development cadence - Management stated that increased R&D spending would not yield immediate results in 2026 but would accelerate product development for future years [80][81] Question: Commercial team reorganization status - Management confirmed that the reorganization of the commercial team is complete and that the new structure is already being implemented [51] Question: Strategy for DSO penetration - Management acknowledged the importance of DSOs and indicated ongoing discussions to enhance partnerships, although significant moves are not expected until 2027 or 2028 [69][70]

Core Viewpoint - LeMaitre Vascular, Inc. is set to release its fourth quarter 2025 financial results on February 25, 2026, followed by a conference call to discuss the results and company outlook [1]. Company Overview - LeMaitre Vascular, Inc. specializes in devices, implants, and services for treating peripheral vascular disease, which affects over 200 million people globally [3]. - The company develops, manufactures, and markets both disposable and implantable vascular devices aimed at vascular surgeons [3].

Core Viewpoint - Abbott Laboratories (NYSE:ABT) is set to release its fiscal fourth-quarter earnings report, which may present opportunities for bullish options traders, despite the stock's recent underperformance [1][5]. Group 1: Company Overview - Abbott is recognized as a healthcare leader, providing financial stability and dividends, making it a suitable long-term investment for multi-year portfolio strategies [1]. - The demand for Abbott's products is largely non-discretionary, meaning that economic downturns do not significantly affect the need for its diagnostics equipment, medical devices, and nutritional products [3]. Group 2: Market Context - The stock has experienced a decline of over 2% at the start of the year and a 7% loss over the past six months, with a notable downturn beginning in mid-October [5]. - Despite the stock's weak performance, analysts remain optimistic about Abbott's future prospects, indicating a lack of short positions against the stock [6]. Group 3: Stock Analysis - Current analysis suggests that the stock is likely to range between $118 and $134 over the next 10 weeks, with a more focused range of $122 to $130 based on second-order analysis [12]. - The Black-Scholes model indicates a potential movement of about 6% up or down by the March 20 expiration date, while a second-order Markovian analysis suggests a narrower range of outcomes [14]. Group 4: Trading Strategy - A bullish trade strategy is recommended, specifically a 125/130 bull call spread expiring on March 20, with a maximum profit potential of 159% if the stock rises above the $130 strike price [20].

Core Viewpoint - LeMaitre Vascular, Inc. is actively engaging with investors through participation in three upcoming healthcare conferences, highlighting its commitment to investor relations and market presence [1]. Company Participation in Conferences - LeMaitre Vascular will present at the following investor conferences: - Jefferies London Healthcare Conference on November 18, 2025, with CFO Dorian LeBlanc presenting at 8:00 AM GMT [2]. - Wolfe Research 7th Annual Healthcare Conference on November 19, 2025, with President David Roberts presenting at 10:40 AM ET [2]. - Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, with CFO Dorian LeBlanc presenting at 3:20 PM ET [2]. Company Overview - LeMaitre Vascular specializes in devices, implants, and services for treating peripheral vascular disease, which affects over 200 million people globally [2]. - The company develops, manufactures, and markets both disposable and implantable vascular devices tailored for vascular surgeons [2].

Core Viewpoint - Stryker Corporation is a leading medical technology company set to announce its fiscal third-quarter earnings for 2025, with analysts expecting a positive earnings report and growth in EPS over the coming years [1][2][3]. Financial Performance - Analysts anticipate Stryker to report a profit of $3.14 per share for Q3 2025, reflecting a 9.4% increase from $2.87 per share in the same quarter last year [2]. - For the full fiscal year 2025, EPS is expected to be $13.50, a 10.8% increase from $12.19 in fiscal 2024, with further growth projected to $14.95 in fiscal 2026, representing a year-over-year rise of 10.7% [3]. Stock Performance - Stryker's stock has underperformed compared to the S&P 500 Index, which gained 13.5% over the past 52 weeks, while Stryker shares only increased by 2.2% during the same period [4]. - The stock also lagged behind the Health Care Select Sector SPDR Fund, which experienced a 7.2% decline [4]. Competitive Landscape - The company's underperformance is attributed to increased competition from Zimmer Biomet, Johnson & Johnson, and Medtronic, particularly in the robotic orthopedics segment, along with macroeconomic pressures such as inflation and wage pressures affecting margins [5]. Analyst Sentiment - The consensus among analysts is moderately bullish, with a "Moderate Buy" rating overall. Out of 28 analysts, 18 recommend a "Strong Buy," 2 suggest a "Moderate Buy," and 8 advise a "Hold" [7]. - The average analyst price target for Stryker is $434.48, indicating a potential upside of 17.7% from current levels [7].

Company Overview - LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease, which affects over 200 million people globally [3] - The company develops, manufactures, and markets both disposable and implantable vascular devices aimed at vascular surgeons [3] Financial Results Announcement - LeMaitre Vascular will release its second quarter 2025 financial results on August 5, 2025, after market close [1] - A conference call is scheduled for 5:00 PM EDT on the same day to discuss the financial results, business highlights, and company outlook [1] Access to Conference Call - Access to the live conference call requires online registration, after which registrants will receive dial-in information and a PIN [2] - The audio webcast will be available live and for replay through the company's investor relations website [2]

Summary of Henry Schein Conference Call Company Overview - **Company**: Henry Schein - **Industry**: Medical Supplies and Devices - **Key Executives Present**: Stan Bergman (CEO), Ron South (CFO), Graham Stanley, Susan D'Onofrio (IR) Core Business Strategy - **BOLD Plus One Strategy**: - **B**: Build high growth, high margin businesses in specialty dental and medical products, targeting 50% of operating income from these by 2027 [4][5] - **O**: Optimize core distribution business for efficiency and customer satisfaction [5] - **L**: Leverage relationships with approximately 300 businesses to enhance sales across different product lines [6] - **D**: Digitalization of dentistry and medicine, including a new global e-commerce platform (GEP) [7][8] - **Plus One**: Advance relationships with suppliers, customers, and investors [9] Financial Performance - **Q1 Results**: Sales growth noted, with EPS growth excluding PPE impact [10][11] - **Earnings Growth Target**: High single digits to low double digits anticipated post-cyber incident recovery [11] Market Trends - **Dental Market**: Stable visit rates to dentists in the U.S., with a shift towards value in product selection [16][18] - **Equipment Stability**: Equipment sales stable, with some fluctuations; digital technology demand remains strong [18][21] - **International Markets**: Varying stability across Europe, with Brazil showing positive trends despite economic challenges [19][20] - **Software Demand**: Growth in software demand, transitioning to a SaaS model for recurring revenue [21][40] Long-term Financial Goals - **Earnings Growth**: Commitment to high single digit to low double digit growth, with 2026 guidance dependent on market momentum and restructuring initiatives [24][25] - **Cost Savings**: Expected $75 million to $100 million in cost savings from restructuring, leaning towards the higher end [25] Restructuring and Optimization - **Restructuring Focus**: Emphasis on optimizing endodontic business and leveraging synergies from acquisitions [28][29] - **Continuous Improvement**: Ongoing process to enhance efficiency and reduce costs, supported by KKR's investment [31] KKR Investment - **Strategic Partnership**: KKR holds approximately 15% stake, providing expertise in margin management and expense control [33][34] - **Negotiating Leverage**: KKR's portfolio may enhance negotiating power with suppliers [36] Capital Allocation Strategy - **M&A Activity**: Historical M&A spending of $300 million to $400 million annually, with a significant increase in 2023 [44] - **Share Repurchases**: $161 million in share repurchases in Q1, with a focus on maintaining a strong stock buyback strategy [46] Key Takeaways - **Misunderstood Aspects**: The effectiveness of the BOLD Plus strategy in driving growth and profitability through high-margin businesses and digital technology [48][49]